Patients with disseminated malignancy who present with microangiopathic hemolytic anemia and thrombocytopenia may be misdiagnosed as thrombotic thrombocytopenic purpura (TTP), resulting in inappropriate plasma exchange treatment, a procedure with major risk, and delay of appropriate chemotherapy. We report the 17 year experience of The Oklahoma TTP-HUS Registry, 1989–2005, and a systematic review of previously published case reports. Ten of 335 consecutive patients in the Oklahoma Registry who were initially diagnosed with their first episode TTP and treated with plasma exchange were subsequently discovered to have disseminated malignancy; only one had a history of cancer. These 10 patients were compared to the 133 concurrent patients with idiopathic TTP.

Disseminated malignancy (n=10)Idiopathic TTP (n=133)P
Data are median values. P-value for neurologic symptoms compares distribution of abnormalities. Number of patients who had ADAMTS13 measured is in parentheses. 8 idiopathic TTP patients never had plasma exchange (PE). 
Age (years) 56 47 0.106 
Sex (% female) 30% 73% 0.008 
Duration of sx (days) 21 0.005 
Presenting sx  
Weakness 70% 53% 0.347 
cough, dyspnea 70% 26% 0.007 
Fever 50% 31% 0.292 
abdominal pain 40% 35% 0.745 
Nausea/vomiting 20% 53% 0.052 
Neurologic abnormalities  
Severe 20% 47% 0.128 
Minor 60% 29%  
None 20% 24%  
Laboratory data  
hematocrit (%) 21 22 0.868 
platelet count (103/ml) 21,000 13,000 0.328 
creatinine (mg/dL) 2.4 2.0 0.761 
LDH (U/L) 2894 1260 0.045 
ADAMTS13  
Median activity (%) 50(8) 23 (81) 0.167 
<5% activity (% of pts) 30% 0.102 
Response to PE 10% 82% (125) <0.001 
Death (within 30 days) 90% 20% <0.001 
Disseminated malignancy (n=10)Idiopathic TTP (n=133)P
Data are median values. P-value for neurologic symptoms compares distribution of abnormalities. Number of patients who had ADAMTS13 measured is in parentheses. 8 idiopathic TTP patients never had plasma exchange (PE). 
Age (years) 56 47 0.106 
Sex (% female) 30% 73% 0.008 
Duration of sx (days) 21 0.005 
Presenting sx  
Weakness 70% 53% 0.347 
cough, dyspnea 70% 26% 0.007 
Fever 50% 31% 0.292 
abdominal pain 40% 35% 0.745 
Nausea/vomiting 20% 53% 0.052 
Neurologic abnormalities  
Severe 20% 47% 0.128 
Minor 60% 29%  
None 20% 24%  
Laboratory data  
hematocrit (%) 21 22 0.868 
platelet count (103/ml) 21,000 13,000 0.328 
creatinine (mg/dL) 2.4 2.0 0.761 
LDH (U/L) 2894 1260 0.045 
ADAMTS13  
Median activity (%) 50(8) 23 (81) 0.167 
<5% activity (% of pts) 30% 0.102 
Response to PE 10% 82% (125) <0.001 
Death (within 30 days) 90% 20% <0.001 

Patients with disseminated malignancy had a longer duration of symptoms, were more often men, had more frequent presence of respiratory symptoms, higher LDH levels, more often failed to respond to plasma exchange treatment, and had a higher mortality. Neurologic abnormalities, hematocrit, platelet count, and serum creatinine were not different between the two groups. Diagnosis of malignancy was made by bone marrow biopsy in 6 patients but not until autopsy in 2 patients. A systematic review identified 19 additional patients, reported from 1965 to 2005, in whom TTP or HUS was initially suspected and systemic malignancy subsequently discovered. Only 5 patients had a history of cancer. Malignancy was not diagnosed until autopsy in 6 patients. Fourteen different malignant disorders were diagnosed in these 29 patients.

CONCLUSIONS: Disseminated malignancy may be occult and may mimic TTP. A search for systemic malignancy, including a bone marrow biopsy, is appropriate when patients diagnosed with TTP have atypical clinical features or fail to respond to plasma exchange.

Disclosure: No relevant conflicts of interest to declare.

Author notes

*

Corresponding author

Sign in via your Institution